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Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) during primary
infection and persists in this compartment by unknown mechanisms over the course of infection. In this study,
we examined viral population dynamics in four asymptomatic subjects commencing antiretroviral therapy to
characterize cellular sources of HIV-1 in the CNS. The inability to monitor viruses directly in the brain poses
a major challenge in studying HIV-1 dynamics in the CNS. Studies of HIV-1 in cerebrospinal fluid (CSF)
provide a useful surrogate for the sampling of virus in the CNS, but they are complicated by the fact that
infected cells in local CNS tissues and in the periphery contribute to the population pool of HIV-1 in CSF. We
utilized heteroduplex tracking assays to differentiate CSF HIV-1 variants that were shared with peripheral
blood plasma from those that were compartmentalized in CSF and therefore presumably derived from local
CNS tissues. We then tracked the relative decline of individual viral variants during the initial days of
antiretroviral therapy. We found that HIV-1 variants compartmentalized in CSF declined rapidly during
therapy, with maximum half-lives of approximately 1 to 3 days. These kinetics emulate the decline in HIV-1
produced from short-lived CD4 T cells in the periphery, suggesting that a similarly short-lived, HIV-infected
cell population exists within the CNS. We propose that short-lived CD4 T cells trafficking between the CNS
and the periphery play an important role in amplifying and maintaining HIV-1 populations in the CNS during
the asymptomatic phase of infection.
Human immunodeficiency virus type 1 (HIV-1) infection of
the central nervous system (CNS) can cause severe neurolog-
ical disease and may also result in the establishment of a
unique viral reservoir that is relatively inaccessible to some
antiretroviral therapies (11, 21, 29, 40). During primary infec-
tion, HIV-1 likely enters the CNS via infected monocytes and
macrophages (20, 22, 39), although the virus might also cross
the blood-brain barrier as cell-free virions, via infected CD4
T lymphocytes, or by direct infection of brain microvascular
endothelial cells (1). Several studies have suggested that mac-
rophage-tropic forms of HIV-1 preferentially invade the brain
(2, 12), and most HIV-1 detected in the brain at autopsy is
found within macrophages and microglia (16, 18, 47).
The mechanisms by which HIV-1 persists in the CNS over
the entire course of infection are largely unknown. Studies of
HIV-1 population dynamics in the periphery during the initi-
ation of antiretroviral therapy have provided a detailed under-
standing of the kinetics of virus infection in vivo and have
revealed the contribution of specific cell types to the HIV-1
population in this compartment (15, 23, 31, 43, 50). Effective
antiretroviral therapies block the infectious cycle by various
means, depending on the drug(s) used, while cells already
infected with HIV-1 can continue to produce viral RNA. As a
result, the decline in HIV-1 RNA during antiretroviral therapy
reflects the life span of virus-producing cells. There are at least
two phases of HIV-1 RNA decay in peripheral blood plasma
during antiretroviral therapy (15, 23, 50). An initial rapid de-
cline reflects the clearance of free virus and the turnover of
short-lived, productively infected CD4 T cells. A subsequent,
more gradual decay is thought to reflect the turnover of long-
lived infected cells such as macrophages and resting CD4 T
cells (15, 42, 50).
We extended these analyses for the present study to include
the CNS compartment to characterize cellular sources of
HIV-1 and to reveal potential mechanisms of HIV-1 persis-
tence in the CNS. A major limitation of evaluating HIV-1
population dynamics in the CNS is the inability to track viruses
directly in the brains of infected subjects. Thus, it has been
necessary to rely on studies of HIV-1 populations in cerebro-
spinal fluid (CSF) to investigate the dynamics of HIV-1 in the
CNS. Several studies have validated the use of CSF as a sur-
rogate source of virus from the brain, and CSF viral loads often
predict the neurological outcome of HIV-1 infection (8, 9, 24,
46, 49). However, although CSF is an integral component of
the CNS, in the context of HIV-1 infection it more accurately
serves as an intermediate compartment between the brain and
the periphery (7, 10, 13). Unique HIV-1 lineages evolve over
time in the brain and peripheral blood, which is most likely a
reflection of different selective pressures on viral replication in
each compartment, whereas viral populations in the CSF ap-
pear to be genetically related to those in both the brain and the
periphery (3, 48, 51). Antiretroviral therapy typically reduces
the amount of bulk HIV-1 RNA in the CSF, and potent anti-
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retroviral therapies have reduced the incidence of HIV-asso-
ciated neurological disease (6, 7, 14, 19, 29). However, it is
uncertain which cellular sources of HIV-1 are affected during
therapy when total viral RNA levels decline in the CSF, since
infected cells in both local CNS tissues and the periphery may
contribute to the population pool of HIV-1 in CSF. Although
it is well established that HIV-1 populations are often com-
partmentalized in CSF, a bulk HIV-1 RNA reduction in CSF
does not necessarily indicate control of the subset of virus
produced from locally infected cells in the CNS.
We utilized a sensitive gel-based system, the heteroduplex
tracking assay (HTA), to distinguish between HIV-1 genetic
variants in CSF arising from peripheral blood from those aris-
ing from local CNS sources. We then monitored by HTA and
phosphorimaging the decline of individual HIV-1 variants dur-
ing the initial days of antiretroviral therapy to characterize the
infected cell types contributing to the viral populations in CSF.
The HTA, a variation of the heteroduplex mobility assay first
described by Delwart et al. (4, 5), is performed by first ampli-
fying a region of the HIV-1 genome by reverse transcription-
PCR (RT-PCR) and then annealing a single-stranded, radio-
actively labeled DNA probe corresponding to the region
amplified by PCR to the PCR product. Clustered mismatches,
insertions, or deletions between the probe and variants in the
PCR product cause kinks and bends to form in the heterodu-
plexes, slowing their migration through a nondenaturing poly-
acrylamide gel and resulting in the display of a mixture of
genotypic variants as a series of distinct heteroduplex bands.
An analysis of highly variable regions of the HIV-1 genome by
HTA reveals the viral population as a complex mixture of
coexisting genotypes, which allows a stringent comparison of
multiple populations within a single patient (17, 35, 39). Unlike
conventional cloning and sequencing methods, the reproduc-
ibility of population sampling is readily validated by HTA.
Therefore, HTA can be used to accurately quantify the relative
contribution of individual genotypic variants to the total viral
population in a biological sample, while detecting variants that
comprise as little as 3% of the total population (38), making it
a useful method for identifying compartmentalized HIV-1 ge-
netic variants in CSF and tracking their decline during antiret-
roviral therapy.
MATERIALS AND METHODS
Study subjects, sampling, and study design. The study subjects, plasma/CSF
sampling, and medication for this study have been previously described (13).
Briefly, blood plasma and CSF samples were obtained at the Vanderbilt Clinical
Research Center (Nashville, Tenn.) from four asymptomatic, treatment-naı̈ve, HIV-
1-infected patients with 200 CD4 T cells/mm3. Plasma samples were collected at
3-h intervals, and CSF samples were collected continuously for 48 h through lumbar
intrathecal catheters. Two rounds of sampling were performed, with the first round
occurring 120 to 72 h prior to therapy and the second round occurring 72 to 120 h
after the initiation of therapy. Patients commenced therapy with stavudine, lamivu-
dine, and nelfinavir at time zero. HIV-1 RNA quantification was determined with
the Nuclisens nucleic acid sequence-based assay (Organon Teknika, Durham, N.C.).
RT-PCR and HTA. Patient samples with viral RNA levels of 10,000 cop-
ies/ml were first concentrated by centrifugation at 25,000  g for 1.5 h prior to
RNA extraction and RT-PCR to allow for sufficient RNA template sampling by
HTA. On therapy, CSF samples from subjects 1 and 4 were pooled and concen-
trated prior to RNA extraction to allow for sufficient template sampling. All
RT-PCR and HTA procedures for all data described were performed indepen-
dently at least twice to validate sampling by ensuring reproducibility in both the
number of HTA variants detected and their relative abundance (as reported by
standard deviation calculations). An RT-PCR blank product was also analyzed
by HTA for each gel to identify single-stranded probe and background bands.
RNA extraction, RT-PCR, and HTA methods (V1/V2 and V3) were performed
as previously described (17, 27, 28). A V4/V5 HTA probe based on the NL4-3
HIV-1 clone was produced and used for HTA by similar methods to those used
for the V1/V2 probe (17). The primers used to clone the NL4-3 V4/V5 region
were HIVenvV4 (HXB2 7349-7378 [5-TTTTAATTGTGGAGGGGAATTTTT
CTACTG-3]) and HIVenvV5 (HXB2 7676-7647 [5-ATATAATTCACTTCTC
CAATTGTCCCTCAT-3]). Heteroduplexes were resolved by electrophoresis in
6% native polyacrylamide gels for V1/V2 and V4/V5 HTA and in 12% gels for
V3 HTA. V3 RT-PCR variants were cloned, screened by V3 HTA to identify
sequences corresponding to individual heteroduplex bands, and sequenced to
predict CCR5 versus CXCR4 coreceptor usage as previously described (25–28,
39).
Phosphorimager analysis and calculations. Phosphorimager screens were ex-
posed to dried HTA gels, and the relative abundance of each variant detected in
all samples was determined by using ImageQuant software (Molecular Dynam-
ics, Sunnyvale, Calif.). Variant RNA concentration data were determined by
multiplying the relative abundance of individual variants by the total HIV-1 RNA
concentrations for those samples. Unpaired, two-tailed Student’s t tests were
used for statistical calculations of CNS compartmentalization and viral RNA
half-lives. Half-life calculations are presented as maximum possible values be-
cause CSF samples were not collected between 0 and 72 h of therapy, a time
when the half-life may have been less (13).
RESULTS
Compartmentalization of HIV-1 variants in CSF. Blood
plasma and CSF samples were obtained prior to the initiation
of three-drug therapy with stavudine, lamivudine, and nelfina-
vir from four asymptomatic, treatment-naı̈ve, HIV-infected
subjects without AIDS. Details regarding these subjects and
the serial CSF and plasma sampling technique are presented
elsewhere (13). HTAs targeting the V1/V2 and V4/V5 hyper-
variable regions of the HIV-1 env gene were used to identify
specific viral RNA variants in plasma and CSF and also to
distinguish CSF variants arising from local CNS tissues from
those shared with the blood. In all four subjects, the pretreat-
ment HIV-1 populations in CSF and plasma clearly differed,
although to varying degrees for different individuals (Fig. 1A).
In particular, multiple variants in the CSF from each subject
were either unique to CSF or were selectively enriched in CSF
relative to plasma, consistent with the conception that produc-
tive viral replication in both peripheral tissues and local CNS
tissues contributes to the HIV-1 population in CSF (3, 7, 13,
48).
The relative and absolute abundances of each HIV-1 RNA
variant detected in blood plasma and CSF were then quantified
(Fig. 1B). While accurately reflecting the relative abundances
of detected variants, absolute variant copy numbers may be
somewhat overestimated because additional minor variants
may be present below the limits of HTA detection. Viral vari-
ants detected in CSF were considered to arise from infected
cells compartmentalized within the CNS if the variants were
either unique to the CSF or present at significantly higher copy
numbers in the CSF versus plasma, because at least a portion
of such variants must be produced from a local source rather
than through equilibration with peripheral blood plasma. Ad-
ditional HIV-1 variants in CSF were selectively enriched more
than twofold in relative abundance but did not have higher
copy numbers than those in plasma (subject 1, V1/V2 variant
C6 and V4/V5 variants C1 and C2) (Table 1). Therefore, we
cannot rule out the possibility that these variants arose entirely
from a peripheral source. Sources of compartmentalized vari-
ants in CSF may include macrophages, microglia, astrocytes,
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and/or trafficking CD4 T cells within the CNS. Viral variants
identified as being compartmentalized within the CNS based
on these criteria are shown in Fig. 1A. In all but one case
(subject 4, V4/V5 variant C8), unique variants detected in the
CSF were present at levels higher than the minimum level of
detection for plasma variants (Fig. 1B). Variants that were
present at higher copy numbers in the CSF versus the periph-
ery were also selectively enriched in CSF an average of 4.3-fold
FIG. 1. Compartmentalization of HIV-1 in the CNS. (A) Blood plasma (P) and CSF (C) samples obtained prior to the initiation of therapy were
subjected to RNA extraction, RT-PCR, and an HTA targeting the V1/V2 or V4/V5 hypervariable region of env to resolve distinct HIV-1 genetic
variants. Single-stranded probe and background bands are indicated by black hexagons for the V1/V2 region for subjects 1 and 2 and the V4/V5
region for subject 3. HTAs with no single-stranded probe band shown had no detectable variant bands that ran near or above the probe; all bands
shown ran below the single-stranded probe. V1/V2 probes produced from the standard HIV-1 molecular clones Ba-L (subjects 1 and 4) and JR-FL
(subjects 2 and 3) were chosen based on the resolution of maximum numbers of variants. The V4/V5 probe used for all four subjects was produced
from the NL4-3 HIV-1 molecular clone. (B) Phosphorimager analysis of V1/V2 and V4/V5 HTA variants detected in panel A. The relative
abundance of each variant detected by HTA was determined and related to the total HIV-1 RNA in all plasma or CSF samples collected prior
to therapy to calculate a value representing the relative copy number of each individual variant. Error bars represent the standard deviations from
a minimum of two independent RT-PCR and HTA analyses of all pretherapy samples. HTA variants that were either unique (*) to the CSF versus
plasma (and significantly above the minimum level of detection for plasma variants) or had a significantly higher copy number in the CSF than
in plasma were considered to be compartmentalized in the CNS and are indicated by arrows in panel A.
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in relative abundance, providing additional evidence that these
variants did not arise exclusively from peripheral tissues. Re-
markably, 11 to 85% of the HIV-1 in CSF was compartmen-
talized in the CNS based on these criteria (Table 1), suggesting
that a large portion of the CSF HIV-1 population in asymp-
tomatic subjects may arise from localized viral replication in
the CNS.
Viral populations in plasma and CSF were also analyzed by
HTA targeting the V3 hypervariable region of env, followed by
cloning and sequencing to predict coreceptor usage based on
the V3 coding sequence. Unlike the V1/V2 and V4/V5 HTAs,
HTA targeting V3 did not reveal considerable levels of com-
partmentalization in the CSF (Fig. 2). Although we did not
detect any V3 variants unique to CSF, relatively minor differ-
ences in the relative abundances of variants in plasma and CSF
were apparent, notably for subject 2. Cloning and sequence
analysis of the V3 variants identified by HTA revealed no
coding sequences associated with CXCR4 usage (25, 26), sug-
gesting that all detectable variants in plasma and CSF for all
four subjects were likely R5-tropic (data not shown).
Dynamics of HIV-1 decline in CSF during antiretroviral
therapy. To examine the decline of compartmentalized HIV-1
RNA variants detected in the CSF, we performed V1/V2 and
V4/V5 HTAs on longitudinal plasma and CSF samples ob-
tained at baseline and during the first 72 to 120 h of antiret-
roviral therapy. By this analysis, slowly decaying variants will
comprise an increasingly larger percentage of the total popu-
lation over time. Therefore, changes in relative abundance
between viral variants after the initiation of therapy reflect the
relative decline of variants and the turnover rates of the in-
fected cells from which they arise.
The concentrations of HIV-1 RNA in blood plasma or CSF
typically must exceed 5,000 copies/ml for reproducible sam-
pling by these HTAs, which is crucial for an accurate quanti-
fication of viral variants. Only subjects 2 and 3 had HIV-1
RNA concentrations above this threshold in CSF samples
taken while they were on therapy (13). We first cloned RT-
PCR products from the CSF of these two subjects and then
screened the clones by HTA and sequencing to confirm that
the identified CNS-compartmentalized variants had distinct
HIV-1 env sequences (data not shown). We then tracked the
relative abundances of all variants in serial plasma and CSF
samples by V1/V2 and V4/V5 HTAs (Fig. 3). Surprisingly, the
relative abundances of the different variants in CSF did not
change appreciably after the initiation of therapy, indicating
that all CSF variants declined at similar rates.
Heteroduplexes were then quantified by phosphorimager
analysis, and the data were related to the total HIV-1 RNA
concentration in each sample to quantify the absolute change
in each CSF variant during the first 72 to 120 h of therapy (Fig.
4). As suggested by the data shown in Fig. 3, CNS-compart-
mentalized variants in CSF declined as rapidly as CSF variants
shared with the blood. In fact, the CNS-compartmentalized
variants from subject 3 appeared to decline more rapidly than
variants shared with the blood.
Samples from subjects 1 and 4 were also analyzed by RT-
PCR and HTA to evaluate the relative decline of all detected
variants, although in most cases reproducibility was obtained
only if the samples were pooled and concentrated to increase
the number of RNA templates (Table 1). As with subjects 2
and 3, all HIV-1 CSF variants from subjects 1 and 4 declined
rapidly during the initial days of therapy. Unexpectedly, CSF
variants that likely arose from local CNS sources declined
somewhat more rapidly than CSF variants shared with periph-
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1d,e 236 0 4.9 3.3 96 (72) 65 (85) 89 59 89 11 69 66 0.637
2 230 13 4.7 4.7 82 (72) 92 (73) 15 88 24 85 92 20 0.060
3 770 3 4.7 4.5 92 (72) 64 (73) 70 53 42 30 77 35 0.003
4d 384 9 4.6 4.1 83 (72) 81 (82) 76 81 35 24 84 31 0.397
a Abbreviations: BL, baseline; WBC, white blood cells; VL, viral load; t1/2 max, average maximum half-life for HIV-1 variants.
b Based on env region that reflected the highest level of compartmentalization in CSF (V1/V2 for subjects 1 and 4 and V4/V5 for subjects 2 and 3).
c Statistical significance of t1/2 max between shared and compartmental variants. Based on two-tailed, unpaired Student’s t test. P values of 0.050 were considered
statistically significant.
d Due to low HIV-1 RNA concentrations, on-therapy samples from subject 1 (for V4/V5) and subject 4 (for both V1/V2 and V4/V5) were pooled and concentrated
to ensure reproducible sampling by HTA. The time points analyzed for viral RNA decline represent the last sample time points used for the pool.
e No CSF viral variants from subject 1 were compartmentalized based on the criteria described in the legend to Fig. 1. However, V1/V2 variant C6 and V4/V5 variants
C1 and C2 were considered compartmentalized for the calculations shown because they were selectively enriched more than twofold in relative abundance in CSF versus
plasma.
FIG. 2. Analysis of the V3 hypervariable region of env by HTA.
Pretherapy RNA samples from plasma (P) and CSF (C) were sub-
jected to RT-PCR and an HTA targeting the V3 region of env, as
previously described, to reveal distinct V3 genetic populations (27, 28).
All bands shown ran below the single-stranded probe band and rep-
resent distinct V3 genetic variants in the biological samples.
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eral blood plasma in all four subjects, although this difference
was statistically significant only for subject 3 (Table 1). These
findings strongly suggest that a population of short-lived HIV-
infected cells within the CNS contributes the vast majority of
compartmentalized virus present in CSF.
DISCUSSION
The mechanisms of HIV-1 persistence in the CNS are poorly
understood, and only a few studies to date have evaluated
HIV-1 population dynamics in this compartment during the
initial days of antiretroviral therapy. Previous studies have
consistently found that bulk CSF viral loads decline rapidly in
asymptomatic subjects commencing therapy (6, 7, 13, 14), in-
dicating that short-lived cells produce the vast majority of
HIV-1 in CSF. There are at least two potential interpretations
of these earlier findings. First, the vast majority of HIV-1
present in CSF during the asymptomatic stage of infection is
produced by short-lived CD4 T cells infected in the periph-
ery, with the treatment of CNS-derived HIV-1 contributing
little to the bulk viral RNA decline in CSF. In this case, a rapid
decline of periphery-derived HIV-1 in the CSF obscures the
slower decline of any CNS-derived variants. Alternatively,
short-lived cells infected in both the periphery and the CNS
contribute to the HIV-1 population pool in the CSF of asymp-
tomatic subjects. Unfortunately, a measure of the overall de-
cline of HIV-1 in CSF during therapy cannot distinguish be-
tween these two possibilities. We therefore determined
whether distinct HIV-1 genetic variants are compartmental-
ized in CSF, which would be indicative of local production of
virus in the CNS, and then measured the relative decline of
individual variants during the initial days of antiretroviral ther-
apy in four asymptomatic subjects. We found that as much as
85% of the HIV-1 population in CSF was enriched and/or
unique to the CSF versus peripheral blood plasma, suggesting
that a significant portion of the HIV-1 population in the CSF
of asymptomatic subjects can be produced from locally in-
fected cells in the CNS. Furthermore, these compartmental-
ized variants declined rapidly during the initial days of therapy,
some more rapidly than CSF variants shared with the periph-
eral blood, suggesting that the vast majority of compartmen-
talized HIV-1 in CSF is produced by short-lived cells.
It is not certain which infected cell types produce the com-
partmentalized HIV-1 variants detected in CSF. Based primar-
ily on autopsy studies of patients who had HIV-associated
dementia, most HIV-1 in the CNS is thought to reside in
relatively long-lived macrophages and microglia (18, 47). The
viruses produced by such cells of the monocyte lineage would
likely decay with a half-life of several weeks or more (15, 50),
rather than the 1 to 3 days we observed for variants compart-
mentalized in the CNS. Although it is conceivable that HIV-
1-infected macrophages and microglia in the CNS turn over
much more rapidly than originally thought, we are not aware of
any evidence in support of this speculation. Similarly, any
HIV-1 that might be produced by astrocytes or neurons would
decline even more slowly during the initiation of therapy since
these cell types are very long-lived.
In peripheral blood, infected, activated CD4 T cells rapidly
turn over, and their clearance corresponds with the rapid de-
cline in HIV-1 RNA in plasma during the initial days of ther-
apy (15, 23, 31, 43, 50). Very few CD4 T cells reside in the
CNS, reflecting its relatively immunity-privileged nature. How-
ever, small numbers of CD4 T cells normally migrate between
the CNS and the periphery, which is important for immune
surveillance in the CNS (37), and some studies have suggested
a relationship between lymphocyte pleocytosis and the HIV-1
load in CSF (30, 36). Infected CD4 T cells in the periphery
FIG. 3. Longitudinal HTA analysis of HIV-1 in CSF and peripheral blood plasma obtained during the initial days of antiretroviral therapy.
Plasma and CSF samples obtained just prior to and immediately after the initiation of antiretroviral therapy were analyzed by an HTA targeting
V1/V2 or V4/V5. Sample time points are shown, with time zero representing the initiation of antiretroviral therapy. CSF variants indicated by
arrows were compartmentalized relative to plasma, with asterisks noting variants unique to CSF versus peripheral blood plasma. The black
hexagons denote single-stranded probe and background bands. Band intensities were maintained in samples taken after the initiation of therapy
by including RNAs extracted from larger volumes of sample.
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are a likely source of HIV-1 variants shared between the CSF
and plasma (Fig. 5). It is also feasible that CD4 T cells
trafficking into the CSF, but originally infected in the periph-
ery, provide a source of shared or enriched variants in CSF
versus plasma. This cannot explain, however, why subpopula-
tions of CD4 T cells appear to be productively infected with
HIV-1 variants unique to CSF.
The most plausible model is that in asymptomatic subjects,
uninfected CD4 T cells migrate from peripheral tissues into
the CNS, where they become infected with HIV-1 produced by
long-lived macrophages and microglia residing in this compart-
ment (Fig. 5). These newly infected CD4 T cells then amplify
monocyte lineage-derived, CNS-compartmentalized variants
to the concentrations found in the CSF. In contrast, CNS
macrophages and resident microglia do not directly contribute
substantial amounts of HIV-1 RNA to the CSF pool of vari-
ants, either because these cells cumulatively produce fewer
virions than CD4 T cells or because viruses cannot access the
CSF from deep brain tissue, where infected macrophages and
microglia may reside. Unique CSF variants are unlikely to arise
from CD4 T cells that became infected in the periphery, since
this would almost certainly make these variants also detectable
in peripheral blood plasma. It is possible that CD4 T cells
alone could sustain the chronic replication of unique variants
entirely restricted to the CNS, although this seems unlikely
given the relatively small and variable number of CD4 T cells
in the CNS. Although coreceptor use does not necessarily
predict HIV-1 neurotropism (12, 44), all viral variants detected
in the plasma and CSF appeared to be R5-tropic based on their
V3 coding sequences, suggesting that these variants probably
have the capacity to replicate in macrophages.
The region of the CNS where CD4 T cells could become
productively infected with HIV-1 is not known. There was no
apparent relationship between CSF leukocyte counts, HIV-1
RNA concentrations in CSF, and CNS-compartmentalized
variant decay (Table 1). However, there are multiple potential
routes of leukocyte entry into the CNS (i.e., not always through
CSF) and several proposed mechanisms of HIV-1 neuroinva-
sion (1, 37), with the added complexity that HIV-1 neuroinva-
sion and leukocyte migration patterns may vary depending on
the disease stage (32–34, 36, 41).
Consistent with this proposed model of HIV-1 compartmen-
FIG. 4. Relative decline of individual HIV-1 genetic variants in CSF during the initial days of antiretroviral therapy. Viral genetic variants in
the CSF detected by longitudinal V1/V2 and V4/V5 HTAs were quantified by phosphorimaging to monitor their relative decline during therapy.
The absolute RNA concentration of each HIV-1 variant was determined by multiplying the percent abundance of the variant by the total viral RNA
concentration in the sample and dividing the result by 100. Each data point represents the average copy number of an individual HIV-1 variant
detected for the indicated sample time point. The 0-h time point shows the mean RNA concentrations for variants detected in all pretreatment
(120 to 72 h prior to the initiation of therapy) CSF samples tested. The line segments illustrate the decline of variants from the averages at the
0-h time point to those at the first CSF sample time point after the initiation of therapy. Dashed line segments indicate CNS-compartmentalized
variants. Error bars represent standard deviations for reproducibility from a minimum of two independent RT-PCR and HTA analyses conducted
for all sample time points shown. Error bars at the 0-h time point represent standard deviations for all replicates of all pretreatment samples
analyzed.
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talization in the CNS, a slower bulk CSF HIV-1 RNA during
therapy has been observed in patients with HIV-associated
dementia and/or advanced AIDS, in contrast with the case for
asymptomatic patients (6, 7, 45), suggesting a greater direct
contribution by infected macrophages and microglia to the
HIV-1 CNS population. These cells are the key mediators of
HIV-1 neuropathogenesis (21), which typically manifests clin-
ically later during infection with the onset of immunodefi-
ciency. Thus, it may be possible to reveal viruses produced
from these long-lived cells by carrying out similar analyses with
samples collected from subjects who have progressed to a more
advanced disease state.
Our findings suggest that trafficking CD4 T cells may play
an active role in the persistence of compartmentalized HIV-1
in the CNS, further illustrating the dynamic nature of HIV-1
populations in this compartment. Although additional studies
are needed to directly observe and characterize the biological
consequences of the infection of trafficking CD4 T cells, our
findings raise the possibility that these cells may contribute to
HIV-1 neuropathogenesis. Our observations also provide new
insights into potential mechanisms of persistence in the CNS
for other neurotropic viruses and suggest that uninfected cells
migrating into various tissue compartments may play an active
role in the maintenance and amplification of a compartmen-
talized viral population.
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